ImmuCell Corporation Restricted Cash and Cash Equivalents
ImmuCell Corporation (ICCC) had Restricted Cash and Cash Equivalents of $1.45 million as of 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Balance Sheet › Assets › Restricted Cash and Investments
us-gaap:RestrictedCashAndCashEquivalents · last filed 2023-08-10
- 2023-06-30: Restricted Cash and Cash Equivalents $1.45M.
- 2022-12-31: Restricted Cash and Cash Equivalents $5.79M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2023-06-30 | $1.45M 10-Q · filed 2023-08-10 |
| 2022-12-31 | $5.79M 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |